IGFBP5 and melanoma: In melanoma, it was shown that DIRC3 activates expression of IGFBP5 through modulating chromatin structure and suppressing SOX10 binding to putative regulatory elements38, suggesting that the two genes at the 2q35 could represent potential therapeutic targets for both melanoma and DTC.